One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Phio Pharmaceuticals Corp.
PHIO · NCM · Healthcare · Biotechnology
Current price
$0.92
52-week range
$0.81 - $4.19
Market cap
$10.65M
Balance sheet
Healthy
-17.73x Concerning
Net cash $13.00M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -113.7% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 8.0% (peer median: 36.0%).
What this company does
Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. is a company developing experimental medicines to help the body fight cancer, primarily by using a technology called INTASYL to target specific genes. Their main focus is on getting these new drugs approved, which means most of their money currently comes from fundraising and potentially partnerships, rather than from selling products. This is important because it highlights that they are still in the early stages of developing their treatments.
How the company got here
Phio Pharmaceuticals, originally founded in 2011 as RXi Pharmaceuticals, has evolved significantly in its journey to develop innovative cancer treatments. The company's foundation is built upon the Nobel Prize-winning discovery of RNA interference (RNAi) by co-founder Craig Mello. Initially, RXi Pharmaceuticals focused on applying its proprietary INTASYL technology, a type of self-delivering RNAi platform, to dermatological and ocular therapies. However, after clinical trials showed promise in these areas, the company strategically shifted its focus in 2017 towards immuno-oncology, believing its technology could offer greater value in treating cancer. This pivotal decision led to the rebranding as Phio Pharmaceuticals in November 2018, signaling a clear commitment to developing cancer therapeutics.
What it actually does
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to creating new ways to fight cancer. They develop treatments using a proprietary technology called INTASYL, which is a type of small interfering RNA (siRNA). Think of siRNA as a tiny biological messenger that can be programmed to 'silence' specific genes within cancer cells. By silencing certain genes, Phio's technology aims to prevent cancer cells from growing unchecked and to help the body's own immune system recognize and attack the tumors more effectively. The company's approach is focused on immuno-oncology, which means harnessing the power of the immune system to combat cancer.
Clinical Segment
Phio Pharmaceuticals operates with a single business segment focused on its clinical development programs. This segment encompasses the research and development of its lead product candidates, PH-762 and PH-894, which are based on the INTASYL technology. The company is currently evaluating PH-762 in clinical trials for various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-894 is in earlier stages of development and targets other cancer types. This focused approach allows the company to concentrate its resources on advancing these specific therapeutic candidates through the rigorous process of clinical testing and regulatory approval.
What management is betting on now
Phio Pharmaceuticals' current strategy is centered on advancing its lead immuno-oncology drug candidate, PH-762, through clinical development. The company is focused on building upon the positive safety profile observed in its Phase 1b clinical study for skin cancers. Key priorities include planning the next stages of clinical development, engaging with regulatory bodies like the FDA for guidance, and ensuring manufacturing readiness for larger-scale trials. Management is also exploring the broader potential of its INTASYL technology platform, which includes numerous other compounds, to identify new therapeutic opportunities in the fight against cancer.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-1.95M
FY2024 Q4
$-1.37M
FY2025 Q1
$-1.28M
FY2025 Q2
$-2.54M
FY2025 Q3
$-2.09M
FY2025 Q4
$-2.08M
FY2026 Q1
$-4.00M
FY2026 Q2
$-4.04M
Revenue
—
Net income
$-4.14M
Diluted EPS
—
Operating cash flow
$-4.04M
Free cash flow
$-4.04M
Fetching…
Sources
Revenue
—
Net income
$-4.00M
Diluted EPS
—
Operating cash flow
$-4.00M
Free cash flow
$-4.00M
Fetching…
Sources
Revenue
—
Net income
$-2.37M
Diluted EPS
—
Operating cash flow
$-2.08M
Free cash flow
$-2.08M
Fetching…
Sources
Revenue
—
Net income
$-2.39M
Diluted EPS
—
Operating cash flow
$-2.08M
Free cash flow
$-2.09M
Fetching…
Sources
Revenue
—
Net income
$-2.17M
Diluted EPS
-0.45
Operating cash flow
$-2.54M
Free cash flow
$-2.54M
Fetching…
Sources
Revenue
—
Net income
$-1.77M
Diluted EPS
-0.41
Operating cash flow
$-1.27M
Free cash flow
$-1.28M
Fetching…
Sources
Revenue
—
Net income
$-1.63M
Diluted EPS
-3.45
Operating cash flow
$-1.37M
Free cash flow
$-1.37M
Fetching…
Sources
Revenue
—
Net income
$-1.52M
Diluted EPS
-1.54
Operating cash flow
$-1.95M
Free cash flow
$-1.95M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.92
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $13.0M - more cash than debt. Interest coverage -17.7x.
Net debt
$-13.00M
Interest coverage
-17.73x
Phio Pharmaceuticals Corp.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
PHIO
BASELINE
Phio Pharmaceuticals Corp.
Total debt $0.00 Interest coverage -17.73x This is the baseline the peer rows are being compared against.
Total debt $1.09M Interest coverage -26.71x Neither company has much profit cushion over interest right now.
Total debt $87.42M Interest coverage -10.31x Neither company has much profit cushion over interest right now.
What you should know
The case for and against PHIO
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -113.7% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 8.0% (peer median: 36.0%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.50x
P/B
0.84x
P/S
—
EV/EBITDA
0.20x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-113.7%
ROA
-65.8%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
8.39x
Quick ratio
7.62x
Total debt
$0.00
Total cash
$13.00M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.29
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-12.20M
Free CF TTM
$-7.99M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—